PAA 0.00% 19.5¢ pharmaust limited

Amylyx class action Relyvrio, page-12

  1. 8,479 Posts.
    lightbulb Created with Sketch. 792
    It seems Riluzole is not so effective as increasing median survival by up to 19 months.

    There is an article online entitled: "Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)."

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055506/#:~:text=The%20results%20indicate%20that%20riluzole,longer%20than%20participants%20taking%20placebo.

    "Riluzole 100 mg daily is reasonably safe and probably prolongs median survival by about two to three months in patients with amyotrophic lateral sclerosis."

    Admittedly that was published back in 2012, so have there been more recent studies on the properties of Riluzole?
 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
(20min delay)
Last
19.5¢
Change
0.000(0.00%)
Mkt cap ! $86.55M
Open High Low Value Volume
19.5¢ 19.5¢ 18.5¢ $330.4K 1.741M

Buyers (Bids)

No. Vol. Price($)
1 4071 19.0¢
 

Sellers (Offers)

Price($) Vol. No.
19.5¢ 24580 3
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
PAA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.